Allergan plc (NYSE:AGN) – Equities research analysts at Cantor Fitzgerald boosted their FY2018 earnings estimates for Allergan in a note issued to investors on Wednesday. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings of $15.90 per share for the year, up from their prior forecast of $15.00. Cantor Fitzgerald has a “Hold” rating and a $191.00 price target on the stock.
Allergan (NYSE:AGN) last issued its earnings results on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, topping the Zacks’ consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The business had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. During the same period last year, the company posted $3.90 earnings per share. The company’s quarterly revenue was up 12.0% compared to the same quarter last year.
Allergan (NYSE AGN) opened at $162.77 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.08 and a current ratio of 2.04. Allergan has a one year low of $157.70 and a one year high of $256.80. The stock has a market cap of $54,610.00, a P/E ratio of -13.58, a PEG ratio of 1.18 and a beta of 1.19.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.77%. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio (DPR) is -23.35%.
In other news, Chairman Brent L. Saunders bought 4,600 shares of the stock in a transaction on Wednesday, December 6th. The stock was bought at an average cost of $164.74 per share, for a total transaction of $757,804.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider William Meury sold 11,807 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. Over the last 90 days, insiders acquired 17,630 shares of company stock valued at $2,890,057. 0.36% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of AGN. Edgewood Management LLC lifted its stake in shares of Allergan by 24.3% during the third quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock worth $911,192,000 after buying an additional 869,248 shares during the period. Baupost Group LLC MA lifted its stake in shares of Allergan by 21.9% during the third quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock worth $607,513,000 after buying an additional 531,600 shares during the period. Asset Management One Co. Ltd. lifted its stake in shares of Allergan by 4,852.6% during the third quarter. Asset Management One Co. Ltd. now owns 503,088 shares of the company’s stock worth $103,108,000 after buying an additional 492,930 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Allergan during the third quarter worth $92,182,000. Finally, Polaris Capital Management LLC lifted its stake in shares of Allergan by 315.4% during the fourth quarter. Polaris Capital Management LLC now owns 500,200 shares of the company’s stock worth $37,195,000 after buying an additional 379,781 shares during the period. Institutional investors and hedge funds own 80.23% of the company’s stock.
WARNING: This story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.com-unik.info/2018/02/10/fy2018-eps-estimates-for-allergan-plc-agn-lifted-by-cantor-fitzgerald.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.